Longeveron Inc. (LGVN): Cash & Equivalents
$4.66M
As of 2025-12-31
$10.08M
As of 2026-06-30
-23.7%
3-year compound annual growth
+41.7%
5-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $4.66M | -75.8% | 2026-03-17, Balance as of period end |
| 2024-12-31 | $19.23M | +288.6% | 2026-03-17, Balance as of period end |
| 2023-12-31 | $4.95M | -52.9% | 2025-02-28, Balance as of period end |
| 2022-12-31 | $10.50M | -59.1% | 2024-02-27, Balance as of period end |
| 2021-12-31 | $25.66M | n/m | 2023-03-14, Balance as of period end |
| 2020-12-31 | $816.0K | n/a | 2022-03-11, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| Longeveron Inc. (LGVN) | 2025-12-31 | $4.66M | -75.8% |
| Neuphoria Therapeutics Inc. (NEUP) | 2026-06-30 | $19.87M | +39.8% |
| China SXT Pharmaceuticals, Inc. (SXTC) | 2026-03-31 | $28.18M | +55.7% |
| Vistagen Therapeutics, Inc. (VTGN) | 2026-03-31 | $30.79M | -54.1% |
| IGC Pharma, Inc. (IGC) | 2025-03-31 | $405.0K | -66.2% |
| Cannapharmarx, Inc. (CPMD) | 2025-12-31 | $1.8K | -16.3% |
| Northwest Biotherapeutics Inc (NWBO) | 2025-12-31 | $3.04M | +39.8% |
| Dare Bioscience, Inc. (DARE) | 2025-12-31 | $24.71M | +57.4% |
| Avenue Therapeutics, Inc. (ATXI) | 2025-12-31 | $2.85M | +10.1% |
Compare LGVN, NEUP, SXTC, VTGN side by side · Screen every company in Pharmaceutical Preparations ↗